fda ban semaglutide on compounded FDA Moves to Close a Compounded GLP-1 Loophole: What the 503B Proposal Means for Patients The pharmaceutical manufacturers of both

Not everyone responds equally to GLP-1 medications like Ozempic

Among T2DM patients on antipsychotics, more patients in the combination group achieved weight loss5% within the study period compared to metformin monotherapy

Pantry snack staples

Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH.

Biomapro Bioma New York City, June 24, 2025 (GLOBE NEWSWIRE) -- In the world of modern health, one truth stands out: your gut is at the core of almost everything